Moderna and Samsung Biologics announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine. Upon execution of the deal, technology transfer will commence immediately at Samsung Biologics' facilities in Incheon, South Korea, utilizing a production line equipped for aseptic fill-finish, labeling, and packaging services to support the production of hundreds of millions of doses of Moderna's COVID-19 vaccine intended for the supply of markets outside of the U.S. starting in the third quarter of 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
166.6 USD | +1.59% | +25.36% | +67.53% |
May. 24 | Novavax awaits FDA decision on whether its next COVID shot can be offered in US | RE |
May. 23 | Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B | |
-8.12% | 11.19B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine